Adrian Quartel
Chief Tech/Sci/R&D Officer at ZEVRA THERAPEUTICS, INC.
Adrian Quartel active positions
Companies | Position | Start | End |
---|---|---|---|
ZEVRA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2024-01-03 | - |
Career history of Adrian Quartel
Former positions of Adrian Quartel
Companies | Position | Start | End |
---|---|---|---|
ACER THERAPEUTICS INC. | Chief Tech/Sci/R&D Officer | 2022-02-21 | 2022-12-31 |
ADAMAS PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2020-08-31 | 2022-01-31 |
BIOMARIN PHARMACEUTICAL INC. | Chief Tech/Sci/R&D Officer | 2016-01-31 | 2020-08-31 |
Training of Adrian Quartel
Erasmus University Rotterdam | Doctorate Degree |
The Royal College of Physicians | Graduate Degree |
Statistics
International
United States | 5 |
Netherlands | 2 |
United Kingdom | 2 |
Operational
Chief Tech/Sci/R&D Officer | 4 |
Doctorate Degree | 1 |
Graduate Degree | 1 |
Sectoral
Health Technology | 5 |
Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
BIOMARIN PHARMACEUTICAL INC. | Health Technology |
ZEVRA THERAPEUTICS, INC. | Health Technology |
Private companies | 2 |
---|---|
Adamas Pharmaceuticals LLC
Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. | Health Technology |
Acer Therapeutics, Inc.
Acer Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Acer Therapeutics, Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of therapies for medical needs. Its product pipeline includes Olpruva, Edsivo, and ACER-801. Olpruva is used for the treatment of urea cycle disorders. Edsivo is a type of celiprolol used in treating Vascular Ehlers-Danlos syndrome. ACER-001 treats menopausal related Vasomotor symptoms. The company was founded by Chris Schelling on March 15, 1991 and is headquartered in Newton, MA. | Health Technology |
- Stock Market
- Insiders
- Adrian Quartel
- Experience